Harold Bernstein, President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 25,156 shares at $40.20 ($1.0M) on 2026-01-07, disclosed to the SEC on 2026-01-09.
Scheduled sale ($1.0M) by President, R&D & CMO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| MAZE | SELL | 2026-09-04 | $270K | — | Filing → |
| MAZE | SELL | 2026-09-03 | $426K | — | Filing → |
| MAZE | SELL | 2026-08-14 | $446K | — | Filing → |